73 related articles for article (PubMed ID: 27539899)
1. The present status of xeroderma pigmentosum in Japan and a tentative severity classification scale.
Nakano E; Masaki T; Kanda F; Ono R; Takeuchi S; Moriwaki S; Nishigori C
Exp Dermatol; 2016 Aug; 25 Suppl 3():28-33. PubMed ID: 27539899
[TBL] [Abstract][Full Text] [Related]
2. Xeroderma Pigmentosum: Part Two: Treatment of Skin Tumors with Topical Podophyllin 25% in Benzoin.
Sharquie K; Jabbar RI; Schwartz RA; Lambert MW; Lambert WC
Skinmed; 2023; 21(5):337-340. PubMed ID: 37945359
[TBL] [Abstract][Full Text] [Related]
3. Psychological correlates of adherence to photoprotection in a rare disease: International survey of people with Xeroderma Pigmentosum.
Walburn J; Canfield M; Norton S; Sainsbury K; Araújo-Soares V; Foster L; Berneburg M; Sarasin A; Morrison-Bowen N; Sniehotta FF; Sarkany R; Weinman J
Br J Health Psychol; 2019 Sep; 24(3):668-686. PubMed ID: 31183946
[TBL] [Abstract][Full Text] [Related]
4. Brazilian XP-E siblings carrying a novel DDB2 variant developed early-onset melanoma: a case report.
de Souza Timoteo AR; Pinheiro de Almeida IC; Yurchenko AA; de Miranda Henriques SR; de Souza Segundo P; Rajabi F; Nikolaev S; Petta TB
BMC Med Genomics; 2023 Aug; 16(1):186. PubMed ID: 37573316
[TBL] [Abstract][Full Text] [Related]
5. Oral mucosa involvement in pediatric patients with xeroderma pigmentosum: a comprehensive review.
Baskurt D; Vural S; Ertekin SS; Baykal C
Int J Dermatol; 2024 Jan; 63(1):59-72. PubMed ID: 37964400
[TBL] [Abstract][Full Text] [Related]
6. Xeroderma Pigmentosum: Novel Prophylactic and Therapeutic Approaches. Part One: Topical Zinc Sulfate 25% and Heat Dermabrasion plus Topical Trichloroacetic Acid.
Sharquie K; Jabbar RI; Schwartz RA; Lambert MW; Lambert WC
Skinmed; 2023; 21(5):330-335. PubMed ID: 37945358
[TBL] [Abstract][Full Text] [Related]
7. Forty years of research on xeroderma pigmentosum at the US National Institutes of Health.
Kraemer KH; DiGiovanna JJ
Photochem Photobiol; 2015; 91(2):452-9. PubMed ID: 25220021
[TBL] [Abstract][Full Text] [Related]
8. Multiple Facial Basal Cell Carcinoma With Xeroderma Pigmentosum.
Wang X; Xie K; Guo X; Bi Z
J Craniofac Surg; 2023 Nov-Dec 01; 34(8):e761-e762. PubMed ID: 37603892
[TBL] [Abstract][Full Text] [Related]
9. Xeroderma pigmentosum group G with pellagroid rash: A rare presentation.
Garg S; Garg K; Thakur V; Behera B
Pediatr Dermatol; 2024; 41(1):150-152. PubMed ID: 37667072
[TBL] [Abstract][Full Text] [Related]
10. Early-onset gynecological tumors in DNA repair-deficient xeroderma pigmentosum group C patients: a case series.
Yurchenko AA; Fresneau B; Borghese B; Rajabi F; Tata Z; Genestie C; Sarasin A; Nikolaev SI
Commun Med (Lond); 2023 Aug; 3(1):109. PubMed ID: 37567969
[TBL] [Abstract][Full Text] [Related]
11. Physical, oral, and swallowing functions of three patients with type a xeroderma pigmentosum: a report of three cases.
Tamura A; Yamaguchi K; Yanagida R; Miyata R; Tohara H
BMC Oral Health; 2024 Feb; 24(1):163. PubMed ID: 38302989
[TBL] [Abstract][Full Text] [Related]
12. Retrospective study of efficacy and adverse events of immune checkpoint inhibitors in 22 xeroderma pigmentosum patients with metastatic or unresectable cancers.
Fernandez ER; Tamura D; Khan SG; Momen S; Fassihi H; Sarkany R; DiGiovanna JJ; Kraemer KH
Front Oncol; 2023; 13():1282823. PubMed ID: 37954081
[TBL] [Abstract][Full Text] [Related]
13. Squamous Cell Carcinoma in African Children with Xeroderma Pigmentosum: Three Case Reports.
Kaloga M; Dioussé P; Diatta BA; Bammo M; Kourouma S; Diabate A; Gueye N; Dione H; Diallo M; Diop BM
Case Rep Dermatol; 2016; 8(3):311-318. PubMed ID: 27920683
[TBL] [Abstract][Full Text] [Related]
14. Alert Regarding Cisplatin-induced Severe Adverse Events in Cancer Patients with Xeroderma Pigmentosum.
Sumiyoshi M; Soda H; Sadanaga N; Taniguchi H; Ikeda T; Maruta H; Dotsu Y; Ogawara D; Fukuda Y; Mukae H
Intern Med; 2017; 56(8):979-982. PubMed ID: 28420850
[TBL] [Abstract][Full Text] [Related]
15. Scalp squamous cell carcinoma in xeroderma pigmentosum.
Awan BA; Alzanbagi H; Samargandi OA; Ammar H
N Am J Med Sci; 2014 Feb; 6(2):105-6. PubMed ID: 24695441
[TBL] [Abstract][Full Text] [Related]
16. SNP Array Screening and Long Range PCR-Based Targeted Next Generation Sequencing for Autosomal Recessive Disease with Consanguinity: Insight from a Case of Xeroderma Pigmentosum Group C.
Nomura F; Shimizu A; Togi S; Ura H; Niida Y
Genes (Basel); 2023 Nov; 14(11):. PubMed ID: 38003022
[TBL] [Abstract][Full Text] [Related]
17. Corneoscleral locally aggressive fibrous histiocytoma in Xeroderma Pigmentosum patient: A case report.
Alkatan HM; Maktabi AMY
Saudi J Ophthalmol; 2019; 33(3):297-299. PubMed ID: 31686974
[TBL] [Abstract][Full Text] [Related]
18. Acceptability and influence of a complex personalized intervention on changes in photoprotection behaviours among people with xeroderma pigmentosum.
Walburn J; Foster L; Araújo-Soares V; Sarkany R; Weinman J; Sainsbury K; Morgan M
Br J Health Psychol; 2023 Nov; 28(4):1113-1131. PubMed ID: 37414737
[TBL] [Abstract][Full Text] [Related]
19. A Japanese girl with mild xeroderma pigmentosum group D neurological disease diagnosed using whole-exome sequencing.
Yokoi T; Enomoto Y; Uehara T; Kosaki K; Kurosawa K
Hum Genome Var; 2020; 7():22. PubMed ID: 32802388
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
